Welcome to the website of Tianjin ouerke Pharmaceutical Technology Co., Ltd !
Tianjin Ouerke Pharmaceutical Technology Co., Ltd
HotLine:

+86-18519864321

HOT KEYWORDS:ELISAACRIDINETRFIA

PRODUCTS

CONTACT US

Tianjin Ouerke Pharmaceutical Technology Co., Ltd

Contacts:Mr.Chi
Email:ethan@kangeryl.com
Mobile:+86-18519864321
Address:guotai road ,dajiangcheng town,wuqing district,tianjin,china

Your location:Home >> PRODUCTS >> ELISA

ELISA

Time:2022-09-13Click:123

- Independent indicator of atherosclerotic plaque vulnerability

Diagnostic reagent for quantitative in vitro determination of lipoprotein related phospholipase A2(Lp-PLA2) in human serum or plasma on photometric systems

Clinical Significance

Atherosclerotic plaque vulnerability-specific inflammatory markers

 

Physical examination and screening of high-risk groups of cardiovascular and cerebrovascular diseases

Recurrence prevention for people with cardiovascular and cerebrovascular diseases

Prognostic evaluation of the population with pre-existing disease

Evaluation of treatment effect

 

Indicator Advantage

 

Specificity: Atherosclerotic plaque, vulnerability specific marker

Independence: independently predicts the risk of atherosclerotic plaque rupture

Accuracy: Quantitative detection, the results are more in line with clinical needs

 

Experts recommend early detection and early prevention

 

In October 2015, "Chinese Expert Recommendations on the Clinical Application of Lipoprotein-Related Phospholipase A2" recommended that the following populations can detect Lp-PLA2 levels to predict the risk of cardiovascular disease events:

Screening of asymptomatic high-risk groups, especially those with intermediate risk of atherosclerotic cardiovascular disease, detection of LP-PLA2 on the basis of traditional risk factor assessment to further assess the risk of future cardiovascular disease.

In patients who have received statin therapy and have good cholesterol control, the level of LP-PLA2 can improve the predictive value of cardiovascular disease event risk.

In patients with acute thrombotic events, including ACS and atherosclerotic ischemic stroke, LP-PLA2 is helpful for long-term risk assessment. For example, combined detection with hs-CRP can improve the predictive value.

 

Features

 

The results of the classic two-step method are stable and accurate

Sample requirements: serum, plasma

Detection range: 10ng/ml-1000ng/ml

Strong specificity and good stability

 

Applicable departments

 

Cardiology, neurology, respiratory, endocrinology, emergency department, laboratory, geriatrics, physical examination center, etc.


Call-center
Hotline

Hotline

+86-18519864321

WeChat
Tianjin Ouerke Pharmaceutical Technology Co., Ltd
TOP